DS
SNTI icon

Daniel Sundheim’s Senti Biosciences Holdings SNTI Stock Holding History

Daniel Sundheim’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-195,000
Closed -$19.4M – 62
2021
Q3 		$19.4M Hold
195,000
– – 0.11% 54
2021
Q2 		$19.4M Buy
+195,000
New +$19.5M 0.13% 46

Other funds holding SNTI

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $212M AUM 100.15% 1-Year Est. Return

Daniel Sundheim's SNTI Position: Q4 2021 in Review

Daniel Sundheim sold out of Senti Biosciences Holdings (SNTI) in Q4 2021, closing a stake of 195,000 shares — an estimated $19.4M sold.

Daniel Sundheim first reported a position in SNTI in Q2 2021 and held it in 2 quarters. The position peaked at $19.4M in Q3 2021. 42 funds tracked by Wall St. Rank hold SNTI as of Q4 2021.

  • Daniel Sundheim reported no remaining Senti Biosciences Holdings position as of Q4 2021 after selling out during the quarter.
  • Daniel Sundheim sold 195,000 Senti Biosciences Holdings shares in Q4 2021, an estimated $19.4M.
  • Daniel Sundheim first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 2 quarters.
  • Daniel Sundheim's Senti Biosciences Holdings position peaked at $19.4M in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q4 2021.

Based on D1 Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.